FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:2759 June 30, 2005 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Edison, R. J. PubMed Citation

To the Editor: In 2004, we reported central nervous system and limb anomalies that followed exposure to statin drugs in the first trimester of pregnancy (April 8, 2004, issue).¹ One case, in which there had been exposure to lovastatin, was described as involving holoprosencephaly on the basis of three separate reports of a "cerebral/brain ventricular septal defect," with accompanying cardiac malformations that had been submitted to the Food and Drug Administration adverse-event database. We recently learned that the manufacturer considered the structural anomalies to be solely cardiac, and therefore we requested source documentation to clarify the conflicting reports. A detailed . . . [Full Text of this Article]

This article has been cited by other articles:

• Belay, B., Belamarich, P. F., Tom-Revzon, C. (2007). The Use of Statins in Pediatrics: Knowledge Base, Limitations, and Future Directions. Pediatrics 119: 370-380 [Abstract] [Full Text]  
• Yi, P., Han, Z., Li, X., Olson, E. N. (2006). The Mevalonate Pathway Controls Heart Formation in Drosophila by Isoprenylation of G{gamma}1. Science 313: 1301-1303 [Abstract] [Full Text]